It is well known that aberrant activation of PI3K/Akt signaling pathway contributed to increased ROS levels in cancer cells by driving many of the molecular mechanisms through direct modulation of mitochondrial bioenergetics and activation of NADPH oxidases (NOXs), or indirectly through the production of ROS as a metabolic by-product [17]. This evidence concerns the gene FMO5 and cancer.